The PARP enzyme inhibitor olaparib is currently undergoing trials to assess its clinical usefulness and cost effectiveness in the treatment of BRCA1/2 mutated HER2− metastatic BC patients following chemotherapy (97). This evidence concerns the gene ERBB2 and breast cancer.